Welcome to our dedicated page for Celgene SEC filings (Ticker: CELG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celgene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celgene's regulatory disclosures and financial reporting.
Bristol Myers Squibb director Phyllis R. Yale reported a routine compensation-related grant of deferred share units. On this Form 4, she acquired 607.428 Deferred Share Units, each economically valued at $57.62, tied to the company’s common stock. These units are part of a non-employee director compensation program and will be converted into common shares when she leaves the board or at a future date she previously selected.
Following this grant, Yale holds a total of 44,986.288 deferred share units, which also reflect deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a non-market, derivative award rather than an open-market stock purchase or sale.
Bristol Myers Squibb director Phyllis R. Yale reported a routine compensation-related grant of deferred share units. On this Form 4, she acquired 607.428 Deferred Share Units, each economically valued at $57.62, tied to the company’s common stock. These units are part of a non-employee director compensation program and will be converted into common shares when she leaves the board or at a future date she previously selected.
Following this grant, Yale holds a total of 44,986.288 deferred share units, which also reflect deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a non-market, derivative award rather than an open-market stock purchase or sale.
Bristol Myers Squibb director Theodore R. Samuels II reported receiving an award of 889.448 Deferred Share Units on June 30, 2026. These units represent deferred compensation tied to the company’s common stock and are granted at a reference price of $57.62 per unit.
Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. According to the terms, settlement occurs when Samuels ceases to be a director or at a future date he previously selected. After this grant and related deferred amounts and reinvested dividends, he now holds a total of 70,360.664 Deferred Share Units directly.
Bristol Myers Squibb director Theodore R. Samuels II reported receiving an award of 889.448 Deferred Share Units on June 30, 2026. These units represent deferred compensation tied to the company’s common stock and are granted at a reference price of $57.62 per unit.
Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. According to the terms, settlement occurs when Samuels ceases to be a director or at a future date he previously selected. After this grant and related deferred amounts and reinvested dividends, he now holds a total of 70,360.664 Deferred Share Units directly.
Bristol Myers Squibb director Derica W. Rice received a grant of deferred share units as part of non-employee director compensation. On this Form 4, Rice was awarded 672.5100 Deferred Share Units at a reference price of $57.6200 per unit, increasing her direct holdings of these units to 41,068.6810. Each unit is designed to convert into one share of common stock upon settlement, which occurs when she ceases to be a director or at a future date she previously selected. The position also reflects deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors, making this a routine, compensation-related equity accrual rather than an open-market trade.
Bristol Myers Squibb director Derica W. Rice received a grant of deferred share units as part of non-employee director compensation. On this Form 4, Rice was awarded 672.5100 Deferred Share Units at a reference price of $57.6200 per unit, increasing her direct holdings of these units to 41,068.6810. Each unit is designed to convert into one share of common stock upon settlement, which occurs when she ceases to be a director or at a future date she previously selected. The position also reflects deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors, making this a routine, compensation-related equity accrual rather than an open-market trade.
Bristol Myers Squibb director Michael R. McMullen received a grant of 607.428 Deferred Share Units, each valued at $57.62. These units represent deferred compensation that will be converted into common stock when he ceases to be a director or at a previously chosen future date.
Following this award, McMullen holds a total of 16,332.540 Deferred Share Units tied to Bristol Myers Squibb common stock, including prior deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a compensation-related equity award rather than an open-market stock purchase or sale.
Bristol Myers Squibb director Michael R. McMullen received a grant of 607.428 Deferred Share Units, each valued at $57.62. These units represent deferred compensation that will be converted into common stock when he ceases to be a director or at a previously chosen future date.
Following this award, McMullen holds a total of 16,332.540 Deferred Share Units tied to Bristol Myers Squibb common stock, including prior deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a compensation-related equity award rather than an open-market stock purchase or sale.
Bristol Myers Squibb director Peter J. Arduini received a grant of deferred share units tied to company stock. He acquired 607.428 Deferred Share Units at an assigned value of $57.62 per unit, each corresponding to one share of common stock.
These units will convert into common stock when he ceases to be a director or on a future date he previously selected. Following this grant, his deferred share unit balance is 72,815.595, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of deferred share units tied to company stock. He acquired 607.428 Deferred Share Units at an assigned value of $57.62 per unit, each corresponding to one share of common stock.
These units will convert into common stock when he ceases to be a director or on a future date he previously selected. Following this grant, his deferred share unit balance is 72,815.595, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Julia A. Haller exercised stock options to acquire 20,460 shares of common stock at $53.76 per share. The transaction on June 15, 2026 was a cash exercise, and she is holding all of the underlying shares.
Following this exercise, Haller directly owns 34,079 shares of Bristol Myers Squibb common stock, and the option covering these 20,460 shares has been fully exercised with no remaining balance.
Bristol Myers Squibb director Julia A. Haller exercised stock options to acquire 20,460 shares of common stock at $53.76 per share. The transaction on June 15, 2026 was a cash exercise, and she is holding all of the underlying shares.
Following this exercise, Haller directly owns 34,079 shares of Bristol Myers Squibb common stock, and the option covering these 20,460 shares has been fully exercised with no remaining balance.
Bristol Myers Squibb executive Wendy Short Bartie, EVP of Corporate Affairs, reported routine equity compensation transactions involving restricted stock units. She exercised 8,040 restricted stock units, each converting into one share of common stock, and a portion of the resulting shares was used to cover taxes.
The filing shows a tax-withholding disposition of 3,876 common shares at $54.72 per share to satisfy tax obligations upon vesting, not an open-market sale. After these transactions, she directly holds 12,081 shares of common stock. The restricted stock units vest annually in three equal installments beginning on June 3, 2025, and were scheduled compensation rather than discretionary trading.
Bristol Myers Squibb executive Wendy Short Bartie, EVP of Corporate Affairs, reported routine equity compensation transactions involving restricted stock units. She exercised 8,040 restricted stock units, each converting into one share of common stock, and a portion of the resulting shares was used to cover taxes.
The filing shows a tax-withholding disposition of 3,876 common shares at $54.72 per share to satisfy tax obligations upon vesting, not an open-market sale. After these transactions, she directly holds 12,081 shares of common stock. The restricted stock units vest annually in three equal installments beginning on June 3, 2025, and were scheduled compensation rather than discretionary trading.
Bristol-Myers Squibb Company reported voting results from its annual shareholder meeting. Shareholders elected all 11 director nominees to serve until the 2027 annual meeting, with each receiving over 1.46 billion votes in favor and substantial broker non-votes recorded.
Shareholders approved, on an advisory basis, the compensation of named executive officers with 1,459,162,310 votes for and 72,490,026 against, and also approved the Company’s 2026 stock award and incentive plan with 1,470,672,957 votes for and 63,896,918 against. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 was ratified. A shareholder proposal to require the board chairperson to be an independent director did not pass, receiving 422,069,323 votes for and 1,109,378,680 votes against.
Bristol-Myers Squibb Company reported voting results from its annual shareholder meeting. Shareholders elected all 11 director nominees to serve until the 2027 annual meeting, with each receiving over 1.46 billion votes in favor and substantial broker non-votes recorded.
Shareholders approved, on an advisory basis, the compensation of named executive officers with 1,459,162,310 votes for and 72,490,026 against, and also approved the Company’s 2026 stock award and incentive plan with 1,470,672,957 votes for and 63,896,918 against. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 was ratified. A shareholder proposal to require the board chairperson to be an independent director did not pass, receiving 422,069,323 votes for and 1,109,378,680 votes against.
Bristol Myers Squibb EVP and Chief Commercial Officer Adam Lenkowsky reported routine equity award activity involving market share units and common stock. On May 1, 2026, he exercised 1,373 market share units into common stock and recorded related adjustments tied to performance factors.
The filing shows 599 common shares were withheld at $58.22 per share to cover taxes upon vesting, which is not an open-market sale. An additional 203 shares were moved in an "other" transaction. Following these changes, he directly holds 20,508 common shares, plus indirect holdings through a spouse and a BMS savings plan.
Bristol Myers Squibb EVP and Chief Commercial Officer Adam Lenkowsky reported routine equity award activity involving market share units and common stock. On May 1, 2026, he exercised 1,373 market share units into common stock and recorded related adjustments tied to performance factors.
The filing shows 599 common shares were withheld at $58.22 per share to cover taxes upon vesting, which is not an open-market sale. An additional 203 shares were moved in an "other" transaction. Following these changes, he directly holds 20,508 common shares, plus indirect holdings through a spouse and a BMS savings plan.
Bristol-Myers Squibb reported first-quarter 2026 total revenues of $11,489 million, up 3% from 2025, as strong demand in its Growth Portfolio and for Eliquis offset generic erosion in legacy cancer drugs and pricing pressure, especially in the U.S.
GAAP diluted EPS rose to $1.31 from $1.20, helped by lower amortization of acquired intangibles, while non-GAAP EPS fell to $1.58 from $1.80 mainly because diabetes royalty income ended in 2025. Operating cash flow was $1,104 million, and the company continues a restructuring plan targeting about $2.5 billion in charges and $2.0 billion in annual cost savings by 2027.
Bristol-Myers Squibb reported first-quarter 2026 total revenues of $11,489 million, up 3% from 2025, as strong demand in its Growth Portfolio and for Eliquis offset generic erosion in legacy cancer drugs and pricing pressure, especially in the U.S.
GAAP diluted EPS rose to $1.31 from $1.20, helped by lower amortization of acquired intangibles, while non-GAAP EPS fell to $1.58 from $1.80 mainly because diabetes royalty income ended in 2025. Operating cash flow was $1,104 million, and the company continues a restructuring plan targeting about $2.5 billion in charges and $2.0 billion in annual cost savings by 2027.